

BRAIN

A JOURNAL OF NEUROLOGY

Volume 142 Part 3 March 2019

Editorial

489 Editorial. *D. M. Kullmann*

Scientific Commentaries

490 Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum. *R. Hohlfeld*

492 How to help cerebellar patients make the most of their remaining learning capacities. *O. Donchin and D. Timmann*

496 Mesolimbic dopamine and anterior cingulate cortex connectivity changes lead to impulsive behaviour in Parkinson's disease. *A. P. Strafella*

498 REM sleep behaviour disorder: an early window for prevention in neurodegeneration? *R. S. Weil and H. R. Morris*

Update

502 Blood-brain barrier pericytes as a target for HIV-1 infection. *L. Bertrand, H. J. Cho and M. Toborek*

Clinical Trial

512 Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. *A. Whone, M. Luz, M. Boca, et al.*

Original Articles

526 Maturation of feedforward toe walking motor program is impaired in children with cerebral palsy. *J. Lorentzen, M. Willerslev-Olsen, H. Hüche Larsen, et al.*

542 PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. *D. L. Johnstone, H. H. Al-Shekaili, M. Tarailo-Graovac, et al.*

560 Biallelic *KARS* pathogenic variants cause an early-onset progressive leukodystrophy. *M. Itoh, H. Dai, S.-i. Horike, et al.*

574 Mutations in the microtubule-associated protein *MAPI1* (*C7orf43*) cause microcephaly in humans and zebrafish. *Y. Perez, R. Bar-Yaacov, R. Kadir, et al.*

586 Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. *S. P. Allen, B. Hall, L. M. Castelli, et al.*

606 Abnormal visuo-vestibular interactions in vestibular migraine: a cross sectional study. *N. F. Bednarczuk, A. Bonsu, M. C. Ortega, et al.*

617 Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. *I. Mexhitaj, M. H. Nyirenda, R. Li, et al.*

633 Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. *D. Eden, C. Gros, A. Badji, et al.*

647 Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis. *A. Ntranos, V. Ntranos, V. Bonnefil, et al.*

662 Can patients with cerebellar disease switch learning mechanisms to reduce their adaptation deficits? *A. L. Wong, C. L. Marvel, J. A. Taylor, et al.*

674 Brain white matter damage and its association with neuronal synchrony during sleep. *E. Sanchez, H. El-Khatib, C. Arbour, et al.*

688 A connectome-based mechanistic model of focal cortical dysplasia. *S.-j. Hong, H.-M. Lee, R. Gill, et al.*

700 CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling. *F. Meng, Z. Guo, Y. Hu, et al.*

719 Dopamine restores cognitive motivation in Parkinson's disease. *S. McGuigan, S.-H. Zhou, M. B. Brosnan, et al.*

733 Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. *J. Hammes, H. Theis, K. Giehl, et al.*

744 Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *R. B. Postuma, A. Iranzo, M. Hu, et al.*

760 Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. *P. Rudge, Z. Jaunmuktane, H. Hyare, et al.*

771 Plasma tau/amyloid- β_{1-42} ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *J.-C. Park, S.-H. Han, D. Yi, et al.*

787 Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease. *Y. Zheng, A. Liu, Z.-j. Wang, et al.*

808 Overt social interaction and resting state in young adult males with autism: core and contextual neural features. *K. Jasmin, S. J. Gotts, Y. Xu, et al.*

Dorsal Column

From the Archives

823 From the Archives. *A. Compston*

Book Review

830 Brain on fire. *R. Dantzer*

Letters to the Editor

e8 Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. *C. Papadopoulou, Y. Hong, E. Ormoyinmi, et al.*

e9 Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. *Y. Allenbach, L. Bolko, S. Toquet, et al.*

e10 Corrigenda

